0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Circuits and Circuit Disorders: Approaches to Neuromodulation Call for Papers and New Initiative With the American Neurological Association and the Annals of Neurology FREE

Roger N. Rosenberg, MD1,2; Eva L. Feldman, MD, PhD3,4,5
[+] Author Affiliations
1Department of Neurology, University of Texas Southwestern Medical Center, Dallas
2Editor, JAMA Neurology
3Department of Neurology, University of Michigan Health System, Ann Arbor
4Past President, American Neurological Association
5Editorial Board Member, JAMA Neurology and Annals of Neurology
JAMA Neurol. 2015;72(4):385. doi:10.1001/jamaneurol.2015.0117.
Text Size: A A A
Published online

The American Neurological Association (ANA) will host the satellite symposium “Circuits and Circuit Disorders: Approaches to Neuromodulation” on Saturday evening, September 26, 2015, in Chicago, Illinois, the evening before the start of the regular scientific program. The symposium is cosponsored by the Annals of Neurology and JAMA Neurology and will be cochaired by the respective editors, Clifford Saper, MD, PhD, and Roger N. Rosenberg, MD. We are pleased with this new relationship and look forward in future years to developing educational programs with the ANA, the Annals of Neurology, and JAMA Neurology.

The program features Mahlon DeLong, MD, Emory University, 2014 Lasker-DeBakey Clinical Medical Research Award recipient, for his research in developing deep brain stimulation (DBS); Philip Starr, MD, PhD, University of California, San Francisco; Jonathan Mink, MD, PhD, University of Rochester Medical Center; Helen Mayberg, MD, Emory University; and Bryan L. Roth, PhD, University of North Carolina.

The scientific program for the symposium represents a comprehensive review of DBS for Parkinson disease since its inception and development by Dr DeLong and his colleagues, followed by comprehensive presentations of the dystonias, Tourette syndrome, obsessive-compulsive disorder, depression, and chemogenetics using designer receptors exclusively activated by designer drugs (DREADDs).

Dr DeLong will review the concepts of circuits, circuit disorders, and associated neurological signs and symptoms. He will emphasize that the introduction of high-frequency DBS more than 2 decades ago, first for tremor and then for Parkinson disease, has led to a renaissance in functional stereotaxic surgery for movement disorders as well as for a wide variety of other neurological and psychiatric disorders. Dr DeLong maintains that DBS is not disease specific but rather circuit specific, since the same target may be used to treat a variety of movement disorders.1,2

Dr Starr will present his work on circuit mechanisms of dystonia using combined cortical and basal ganglia recordings in humans undergoing DBS. He will present his findings that support the view that generalized dystonia and Parkinson disease may have physiologic overlap with respect to motor cortex synchronization and resting-state activity.

Dr Mink’s presentation will focus on the results of recent studies of DBS in Tourette syndrome and obsessive-compulsive disorder, current controversies, and emerging directions, while Dr Mayberg will discuss DBS as an emerging experimental treatment strategy for patients with intractable major depression.

Dr Roth will summarize DREADDs, the chemogenetic platform that provides remote control of neuronal activity in a cell type–specific and noninvasive manner. He will then highlight applications of this technology as a therapeutic approach for a variety of neurological disorders and how chemogenetic technologies induce the sequential multimodal control of neurons in freely moving animals.

JAMA Neurology welcomes manuscripts submitted to us on these subjects by May 1, 2015, so that they can be peer reviewed in the standard manner and be published as an Online First article during the same month as the symposium and subsequently in print as a Theme Issue on “Circuits and Circuit Disorders: Approaches to Neuromodulation.”

Registration for the ANA meeting and a hotel reservation can be obtained by going to http://myana.org/events/ana-2015-annual-meeting.

This symposium is the prologue to an excellent scientific program of the 140th Annual Meeting of the ANA. We hope you will begin this outstanding educational opportunity provided by the ANA by attending this symposium and experiencing a first-rate scientific discussion on neuromodulation and the anticipated future developments in this dynamic and rapidly emerging field of neurology.

ARTICLE INFORMATION

Corresponding Author: Roger N. Rosenberg, MD, Department of Neurology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9108 (roger.rosenberg@utsouthwestern.edu).

Published Online: March 2, 2015. doi:10.1001/jamaneurol.2015.0117.

Conflict of Interest Disclosures: None reported.

REFERENCES

DeLong  MR, Benabid  AL.  Discovery of high-frequency deep brain stimulation for treatment of Parkinson disease: 2014 Lasker Award. JAMA. 2014;312(11):1093-1094.
PubMed   |  Link to Article
Rousseaux  MWC, Zoghbi  HY.  Deep brain stimulation for Parkinson disease: the 2014 Lasker-DeBakey Clinical Medical Research Award [published online January 5, 2015]. JAMA Neurol. doi:10.1001/jamaneurol.2014.4109.

Figures

Tables

References

DeLong  MR, Benabid  AL.  Discovery of high-frequency deep brain stimulation for treatment of Parkinson disease: 2014 Lasker Award. JAMA. 2014;312(11):1093-1094.
PubMed   |  Link to Article
Rousseaux  MWC, Zoghbi  HY.  Deep brain stimulation for Parkinson disease: the 2014 Lasker-DeBakey Clinical Medical Research Award [published online January 5, 2015]. JAMA Neurol. doi:10.1001/jamaneurol.2014.4109.

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

1,978 Views
0 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
Jobs